News
World Hemophilia Day 2025
On this World Hemophilia Day 2025, we come together to raise awareness, celebrate progress, and reaffirm our commitment to supporting those affected by bleeding disorders, with a special focus on women and girls. This year, we reflect on the strides we’ve made in recognizing and diagnosing bleeding disorders in females, marking 15 years for the Foundation for Women & Girls with Blood Disorders. However, we also acknowledge that there’s still much work to be done.
The medical community has made significant progress in understanding the impact of bleeding and other blood disorders on women and girls. Through collaborative partnerships in the blood disorder community, we emphasize that women can also inherit hemophilia and other blood disorders, experiencing symptoms like heavy menstrual bleeding, easy bruising, and even spontaneous bleeds. Advances in genetics, early diagnosis, and tailored treatment options have empowered women to manage their condition more effectively and live fuller lives.
As we celebrate World Hemophilia Day, let’s honor the strength of women and girls living with bleeding and other blood disorders, commit to breaking down barriers, raising awareness, and advancing research. Together, we can create a world where all those affected by these bleeding disorders receive the care and support they so deserve.
To this end, FWGBD would like to announce a special symposium to be held this summer, preceding the ISTH Congress:
Our symposium, “It’s About Time: Defining Clinical Endpoints in Bleeding for Studies of Women & Girls” will convene leading experts to address the critical gap in clinical research related to women with bleeding and other blood disorders. Focusing on trauma and surgery, menstruation, and obstetrics, the symposium will examine how to define meaningful, feasible endpoints for abnormal reproductive tract bleeding across a woman’s lifespan.
A highlight of the event will be a special panel discussion that will explore the shared challenges and successes in the inclusion of women in clinical studies, with a specific focus on how menstrual and obstetric bleeding have been addressed to date, the use of clinical endpoints specific to women and the barriers to establishing them, and strategies to increase participation of women in future clinical work, particularly those with blood disorders.
